MorphoSys acquires Lanthio’s lanthipeptide technology
The acquisition is part of an ongoing collaboration and option agreement signed by the two companies in November 2012. As part of the acquisition, MorphoSys now has lanthipeptide
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.
The newly issued patents expand the already large intellectual property estate surrounding BMP-7, which include over 450 issues and pending patents, and extends important intellectual property in OA
Jean-Philippe Langevin, M.D., an expert in neurotrauma and a neurosurgeon at the Veterans Affairs Greater Los Angeles (VAGLA) medical center, will lead the study as Principal Investigator. The
The company also announced the establishment of its corporate headquarters in Cambridge, Massachusetts, where Patrick Anquetil, Ph.D., MBA and Mark Philip, Ph.D., MBA serve as chief executive officer
The results show that AG014 is safe and well tolerated while providing localized gastro-intestinal (GI) exposure. AG014 is the company’s ActoBiotics delivery platform and works by expressing and